Form Type:  8-K
Filing Date:  5/20/2014 
CIK:  0001010086 
Address:  27 EAST 62ND STREET 
City, State, Zip:  NEW YORK, New York 10065 
Telephone:  212-672-9100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.19 (2.83%)  
Trade Time: 
Jun 22  
Market Cap: 
Trade SIGA now with 

© 2018  
Description of Business
SIGA Technologies, Inc. is referred to throughout this report as "SIGA," "the Company," "we" or "us." We are a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. A new drug application ("NDA") for TPOXX® was submitted to the United States Food & Drug Administration ("FDA") in December 2017. In February 2018, the Company received notice that the FDA granted priority review of the NDA and that the FDA's target final action date is August 8, 2018. While TPOXX® is not yet approved as safe or effective by the FDA, it is a novel small-molecule drug that is being delivered to the U.S.
Register and access this filing in:     
  FORM 8-K
      Item 5.07. Submission of Matters to a Vote of Security Holders.